MyFinsight
Home
Blog
About
EYLEAHD
$596,300K
Eylea Net Product
Sales
$412,200K
(-45.35%↓ Y/Y)
US
$342,600K
(38.26%↑ Y/Y)
Non Us
$146,800K
(14.06%↑ Y/Y)
EYLEAHDAnd EYLEA-US
$1,008,500K
LIBTAYONet Product Sales
$489,400K
(29.99%↑ Y/Y)
Praluent Net Product
Sales-US
$74,700K
(13.53%↑ Y/Y)
Evkeeza-US
$53,300K
(29.37%↑ Y/Y)
Lynozyfic
$16,500K
Collaboration Revenue
$2,455,000K
(31.94%↑ Y/Y)
Product
$1,642,400K
(0.70%↑ Y/Y)
Product And Service
Other
$193,300K
(5.11%↑ Y/Y)
Revenues
$4,290,700K
(16.73%↑ Y/Y)
Other income
(expense), net
$245,300K
(-44.60%↓ Y/Y)
Income from operations
$1,293,500K
(19.82%↑ Y/Y)
Total other income
(expense)
$234,300K
(-46.65%↓ Y/Y)
Total expenses
$2,997,200K
(15.45%↑ Y/Y)
Interest expense
$11,000K
(205.56%↑ Y/Y)
Income before income
taxes
$1,527,800K
(0.60%↑ Y/Y)
Research and development
$1,631,600K
(14.76%↑ Y/Y)
Selling, general, and
administrative
$662,100K
(4.40%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$360,700K
(30.88%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$215,800K
(-15.24%↓ Y/Y)
Acquired in-process
research and development
$127,000K
(1170.00%↑ Y/Y)
Net income
$1,296,900K
(-6.81%↓ Y/Y)
Gain on foreign
currency translation
$300K
(-76.92%↓ Y/Y)
Income tax expense
$230,900K
(81.67%↑ Y/Y)
Comprehensive income
$1,249,200K
(-11.72%↓ Y/Y)
Unrealized (loss) gain on
debt securities
-$48,000K
(-317.19%↓ Y/Y)
Back
Back
Income Statement
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
source: myfinsight.com